atezolizumab approval for advanced alveolar soft part sarcoma (IMAGE)

NIH/National Cancer Institute

atezolizumab approval for advanced alveolar soft part sarcoma

Caption

Left frame: Normally, tumor cells (purple) evade the immune system’s T cells (pink) by expressing a checkpoint protein known as PD-L1. Right frame: Atezolizumab (Tecentriq) binds to PD-L1 and blocks it from binding to another checkpoint protein, PD-1. This helps T cells regain their ability to kill tumor cells.

Credit

Credit for image: Credit: Adapted from Onco Targets Ther 2017. doi: 10.2147/OTT.S90459. CC BY 3.0. The Creative Commons Attribution License 3.0 (“CC BY 3.0”) is a public domain license which permits most forms of use or re-use of a licensed work provided that (a) due acknowledgement is made of the original source and authorship

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.